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METHODS 
Case Material THE recently discovered phenomena of bidirectional cell migration and consequent systemic as well as 
graft chimerism have been proposed to be essential for the 
long-term acceptance of any kind of whole organ graft. 1.2 
Under effective immunosuppression, donor passenger 
cells that are of monocyte/macrophage and other lineages 
of bone marrow origin pass from the graft into ubiquitous 
recipient tissues while similar leukocytes from the recipi-
ent replace them in the transplant. 3-5 We have postulated 
that the bodywide engagement results in initial mutual 
activation of these coexisting immunocyte populations, 
leading in successful cases to variable donor and recipi-
ent-specific no nreactivity .1,2 This implies the eventual 
possibility in some patients of achieving immunologic 
tolerance and a drug-free state. Because these migratory 
cells are more densely represented in the liver we pre-
dicted that this desirable end point would be achieved 
most frequently with this organ. We report some clinical 
and immunologic observations that are congruent with 
this hypothesis. 
Group I, Noncompliance. Eight patients stopped their medica-
tions 0.5 to 1 J years after transplantation; seven have remained 
drug free for I to 14.3 years subsequently. One of these patients 
underwent a second successful transplantation in April 1992, 12 
years after the first grafting, but had been off immunosuppression 
for 7.7 years. The liver had been destroyed by chronic viral 
hepatitis (hepatitis C virus [HCV]) and contained no evidence of 
rejection (Case 6, Table 1). 
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Table 1. Noncompliance and Physician-Directed Drug Weaning 
TIme Post-Tx 
Patient Age at Tx FlU Post·Tx off Medication Total Time 
No. Diagnosis (y) (y) Previous immunosuppression (y) off (y) Liver Function 
Group I (noncompliant) 
1 Biliary atresia 4 19.7 Azathioprine/prednisone 9 10.7 Nonnal 
2 Chronic active 11 18.6 Azathioprine/prednisone 11 7.6 Nonnal 
hepatitis 
3 Biliary atresia 0.8 15 Azathioprine/prednisone 10 5 Normal 
4 Secondary biliary 15 14.8 Azathioprine/prednisone 0.5 14.3 Normal 
cirrhosis 
5 Wilson's disease 21 13.5 Azathioprine/prednisone 2 11.5 Normal 
6' Chronic active 28 12.7 Cyclosporine/prednisone 5 7.7 Failed re-Tx, 
hepatitis well 
7 Alagille's syndrome 2 9.8 Cyclosporine/azathioprine/ 8 1.8 Normal 
prednisone 
8 Chronic active 9 8.7 Cyclosporine/prednisone 7.7 Nonnal 
hepatitis 
Group II (physician wean) 
9 Biliary atresia 3 20.3 Azathioprine/prednisone 20 0.3 Normal 
10 Primary biliary 30 17.3 Azathioprine/prednisone 16.8 0.5 Normal 
cirrhosis 
11t Primary biliary 35 13.7 Azathioprine/prednisone 13.4 0.3 Normal restart 
cirrhosis 
12 Biliary atresia 4 9.4 Cyclosporine/prednisone 8.7 0.7 Normal 
13 Alagi/le's syndrome 6 10.2 Azathioprine/prednisone 9.6 0.6 Normal 
'ReqUired retransplantation jor chroniC hepatitiS C 7 years after primary Tx. Presently on immunosuppression. 
tDeveloped enzyme elevation requinng reinstitution of immunosuppression. 
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Table 2. Group III Patients: Treatment Stopped Because of Complications 
Time Post-Tx 
Age of Tx Previous Taken off Total Time Type of Liver 
Patient No. Diagnosis (y) immunosuppression Medication (y) off (y) Inlection Function 
14 Biliary atresia 3 Cyclosporine/prednisone 6 3.6 HIV Normal 
15 Polycystic liver disease 15 Cyclosporine/prednisone 8 0.5 PTLD Normal 
1B' Biliary atresia 5 Cyclosporine!prednisone 7 2.8 HIV Failing 
Azathioprine! ATG/OKT3 
17 Biliary atresia O.B FK 506!prednisone 1.2 2.B PTLD Normal 
18 Neonatal hepatitis 0.3 FK 50B/prednisone 0.8 1.9 PTLD Normal 
19 Fulminant hepatitis C 1 FK 506/prednisone 0.5 2.6 HCV Normal 
20 Biliary atresia 0.6 FK 506/prednisone 0.8 2.3 PTLD Normal 
21 Biliary atresia FK 506/prednisone 1.3 1.1 PTLD Normal 
22 Biliary atresia 1.3 FK 506/prednisone 2 0.9 HCV Normal 
23t Cats eye syndrome 1.5 FK 506/prednisone 1.3 PTLD Re-Tx 
'Liver dysfunction associated with terminal AIDS. 
tDied after retransplantation for chronic hepatitis C infection. 
Of the 8 patients, the first 6 (Table 1) were among 44 who were 
alive in June 1992 after having survived for 10.5 to 22.5 years. The 
high rate of noncompliance (6 of 44, 14%) reflected the word of 
mouth news within this closely knit group that drugs were being 
successfully stopped by others·. This was coupled with the infor-
mation that immunosuppression-related complications had been 
the most common cause of late death of seven other original 
members of their one decade survivor club after 11.1 to 18.4 
postoperative years. None of these late deaths had been caused by 
rejection.4 
In addition, two pediatric recipients who were taken off their 
medication by their parents 7 to 8 years posttransplantation have 
been drug free for 1 and 1.8 years (Table 1). 
Group II. Physician Wean. Physician-directed drug weaning 
was carried out in five other long-surviving recipients who had 
been rejection free for at least 5 years (Table 1). With total 
posttransplantation follow-up of9 to 20 years, four have been drug 
free for 4 to 8 months. Baseline immunosuppression was reinsti-
tuted in one patient (Table 1). 
Group III, Infectious Complications. Ten pediatric recipients 
had immunosuppression stopped 6 months to 8 years after trans-
plantation because of infectious complications: posttransplant 
lymphoproliferative disease (n = 6), HeV (n = 2), and human 
immunodeficiency virus (HIV) (n = 2) (Table 2). One of the 
children underwent unsuccessful retransplantation because of 
progressive chronic viral hepatitis. The other 8 patients have been 
off immunosuppression for 6 months to 3.6 years (Table 2). 
Weaning Regimen 
Most of the noncompliant patients stopped their medica-
tions sporadically at first, and then completely when 
nothing happened. Physician-directed weaning was per-
formed by the systematic decrease in the baseline immu-
nosuppression, starting with drugs having a specific side 
effect such as renal dysfunction, neurotoxicity, hyperten-
sion (cyclosporine [CyA] or FK 506). Steroids and CyA 
were weaned more aggressively in the presence of facial 
brutalization and growth retardation. Liver function was 
assessed biweekly by routine liver function tests (bilirubin, 
alanine transaminase [ALT], aspartate transaminase 
[AST], gamma-glutamyl transpeptidase [GGTj). In the 
HeV Dead 
event of abnormal results, repeat sampling was requested 
and followed by a percutaneous liver biopsy if indicated. 
Rejection was treated in the standard way. 
Chimerism Studies 
Chimeric cells in whole organ recipients were identified by 
the distinctive features of chromosomes 2 (sex) and 6. In 
females who had been given an organ from a male donor, 
the presence in recipient tissues (or blood) of cells with the 
Y chromosome was considered unequivocal evidence of 
systemic chimerism. Alternatively, probes were used that 
detected HLA alleles of chromosome 6. For study of 
either the Y chromosome or chromosome 6, one or the 
other of two technologies, and usually both, were ex-
ploited: (1) immunostaining, which allows the location and 
morphologic characterization of phenotypically distinct 
donor and recipient cells; and (2) polymerase chain reac-
tion (peR), which distinguishes donor from recipient 
DNA. These techniques have been described in detail 
elsewhere. 3-5 
In Vitro Immunologic Studies 
In vitro studies were performed to assess different 
T-helper subsets that are activated during Epstein-Barr 
virus (EBV) infections, assessing the release of various 
cytokines (THI vs TH2) that may influence (augment or 
suppress) the immune response of the host to the allograft. 
Studies were also performed to assess proliferation to third 
party alloantigens. 
Mitogen-Induced Proliferation. Mononuclear cells were iso-
lated by Ficoll Hypaque gradient from heparinized peripheral 
blood samples of the pediatric liver transplant recipients. Lym-
phocytes (S x 104 cells/well) were cultured in tissue culture media 
supplemented with 5% pooled human serum, for 72 hours in 37°C 
in the presence of either concanavalin A (ConA, 4 fLmlmL) or 
phytohemagglutimn (PHA. 10 /-LmlmL). Proliferation was as-
sessed by 3H-thymidine uptake for the last 20 hours of incubation. 
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Mixed Lymphocyte Reaction. Unidirectional MLR cultures 
were set up with 5 x 104 cells/well of irradiated normal unrelated 
lymphocytes (third party cells) in tissue culture medium for 6 
days. Proliferation was assessed by 3H-thymidine uptake for the 
last 20 hours of incubation. 
Homozygous Typing Assay. This assay was set up using pa-
tients' peripheral blood lymphocytes (PBL) as responders and 
homozygous typing cells (HTC) as stimulators following the 
standard protocol of MLR as described above. HTCs for seven 
different Dw specifics were tested with two to three HTCs per 
specificity. 
DeteClion of Cytokine Gene Expression by Reverse Tran-
scriptase Polymerase Chain Reaction (RT-PCR). Total RNA was 
extracted from 2 x 106 pelleted PBL using RNAzol B. Quantita-
tion of RNA was performed spectrophotometrically. A known 
aliquot of total RNA was used as a template for cDNA synthesis. 
Subsequently, this first strand cDNA was used as a template for 
PCR amplification carried out for 30 cycles using custom made 
oligonucleotide amplimers. The PCR products were analyzed by 
gel electrophoresis on 2% agarose gel stained with ethidium 
bromide. Both positive and negative control samples for each 
primer were included in each analysis and B-actin served as 
positive control for peR reaction. We tested the presence ofIL-2, 
IL-4, IL-6, and IL-lO mRNA in patients' PBL samples before and 
after PHA stimulation. 
RESULTS 
Chimerism 
The first six patients in Group I were all shown to have 
systemic chimerism with both cytostaining (immunocyto-
chemical or Y chromosomes or both) and PCR These 
results have been reported case by case elsewhere.3 ,4 With 
the same techniques, chimerism was demonstrated in 
Patients 9 to 11 of Group II and Patient 17 of Group III. 
Biopsies were not performed on the others because all 
chronically surviving liver recipients studied during the 
last year (n > 50) had chimerism. Thus, multiple biopsies 
without an explicit purpose (such as study of graft-vs-host 
disease [GVHD]) are no longer performed routinely in 
liver recipients. 
Clinical Outcome 
These data are summarized in Table 1 for Groups I and II 
and in Table 2 for Group III. The ability to stop treatment 
was not specific to any of the azathioprine, CyA, or FK 
506-based regimens used throughout the more than two 
decades of case accrual. 
The absence of rejection after drug stoppage was strik-
ing. Patient 11, whose original disease was primary biliary 
cirrhosis (PBC), was returned to therapy 3 months after its 
discontinuance when transaminases rose 10-fold from 
baseline (highest 120 IV) without jaundice. After treatment 
with steroids and reinstitution of azathioprine, liver func-
tion became normal. 
The loss of the liver in Case 6 (an adult) was unequivo-
cally due to recurrent viral chronic active hepatitis as 
reported in detail elsewhere.4 The same disease was re-
sponsible for the graft loss in Patient 23 who also had 
PTLD, which regressed after stopping immunosuppres-
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Table 3. Proliferative Responses of PBl From Pediatric Liver 
Transplant Recipients off Immunosuppression (Group II) 
Patient No. Background 
17 1,052 
20 641 
21 1,014 
22 288 
23 765 
Proliferative Responses 
(cpm) 
eONA PHA 
12,491 71,502 
31,228 161,167 
nt 188,434 
41,979 131,683 
18,451 58,385 
MLR 
88,111 
23,035 
72,061 
47,158 
53,519 
sion; he died after retransplantation. Patient 16 (a child) 
who is dying of acquired immunodeficiency syndrome 
(AIDS), has had this diagnosis with slowly worsening 
condition for almost 10 years, since the early postoperative 
period. His AIDS complications are cryptosporidium gas-
troenteritis and toxoplasma meningoencephalitis. 
The course of Patient 15 who received a kidney and liver 
from the same donor on November 18, 1984 was instruc-
tive. This child with PTLD associated with EBV infection 
was initially treated for this complication with a reduction 
in immunosuppression and IV acyclovir. Because of bouts 
of recurrent PTLD in the following 12 months, immuno-
~uppression was stopped. Two months later, she pre-
sented with elevations of the ALT + AST (10 times 
normal). Rejection was diagnosed on a liver biopsy that 
revealed portal tracts infiltrated with lymphocytes and 
eosinophils. Although endothelitis and bile duct damage 
also were seen on the biopsy, immunosuppression was not 
restarted because of the PTLD threat. The liver enzyme 
profile became normal after 4 weeks and has remained so. 
Immunologic Studies 
It was previously shown that adult liver reCIpIents are 
immunocompetent with or without maintenance immuno-
suppression.4 Five pediatric patients who had immunosup-
pression withdrawn from 0.9 to 2.6 years earlier because of 
infectious complications all had normal mitogen (ConA 
and PHA)-induced proliferation of PBLs, and normal 
MLR response to third party lymphocytes (Table 3). 
Donor cells were not available for MLR testing, how-
ever, we could demonstrate donor-specific hyporeactivity 
in two of these recipients by using the HTC assay. The 
proliferative responses to HTCs that express donor 
HLA-DR antigen were low and in the same range as the 
responses observed towards stimulators that present self 
HLA-DR antigens. Both self and donor-specific responses 
were less than 50% of the proliferative responses towards 
unrelated third party stimulator (Table 4). 
Cytokine mRNA profile ofPBL in three of four patients 
showed the presence ofIL-4, IL-W, and IL-6 mRNA prior 
to PHA stimulation. Following activation, all PBL samples 
showed IL-2, IL-4, IL-6, and IL-lO mRNA (Table 5). 
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Table 4. Homozygous Typing Assay to Detect Donor-Specific 
Hyporeactivity of PBl From Pediatric Liver Transplant 
Recipients (Group III) 
Donor Third Party 
Responder Self Antigen' Antigen' Antigen' 
17 10,765:!: 167 4,229:: 811 21,159:t 1,740 
(n = 3) (n = 3) (n = 6) 
20 4,483 ::':: 1,047 5,017::':: 544 15,376 ::':: 1,874 
(n = 4) (n = 6) (n = 6) 
Note: Proliferative responses (mean ± SE cpm). 
'Stimulator cells (n) were used in MLR that express self DR antigens, 
donor-specific DR antigens, or urlrelated third party DR antigens. 
DISCUSSION 
The hypothesis that cell migration and chimerism explain 
graft acceptance and constitute the seminal step toward 
donor-specific nonreactivity and immunologic tolerance l- 5 
is consistent with the results of in vitro tests in the 
pediatric liver recipients in this case collection, and in a 
larger series of adults reported elsewhere.4 Both the adults 
and children appeared to be fully immunocompetent, and 
in the adult studies, long-surviving recipients were not 
distinguishable according to whether drug therapy had 
been stopped. This implied donor-specific nonreactivity 
just as in the children herein reported, but the unavailabil-
ity of donor cells precluded direct testing this with MLR. 
However, in two of the children, the results of HTC assay 
appeared to be confirmatory of donor-specific nonreactiv-
ity. 
Of interest also was the cytokine proille of four children 
whose immunosuppression was stopped 6 to 15 months 
after transplantation because of PTLD, and not started 
again. One to 2.6 years later (long after clinical recovery), 
the resting PBL cytokine pattern of a negative IL-2 with 
positive IL-4, 6, and 10 suggested the TH-2 immune 
response that has been associated with systemic or local 
donor-specific nonresponsiveness and graft acceptance.6•7 
The inherent responsiveness ofthe PBL wa.s demonstrated 
with PHA stimulation. These observations were consistent 
Table 5. Cytokine mRNA Profile of PBl Samples From Pediatric 
Liver Transplant Recipients off Immunosuppressive Drugs 
(Group III) 
Cytokine mANA 
Patient No. Sample' Actin IL-2 IL-4 IL·6 IL-10 
17 PBl + + + 
PBl-PHA -+- + + ++ ++ 
18 PBl + ++ ++ ++ 
PBl-PHA + + 
19 PBL -i- ++ 
P8l-PHA + + ++ ++ 
20 PBl + ++ ++ ++ 
PBL-PHA + + + ++ + 
'2 x 106 mononuclear cells obtained by Ficoll Hypaque centrifugation from 
PBLs were tested for cytokine mANA before and after 2 hours PHA stimulation. 
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with our contention that aUograft tolerance is an active 
process that requires continuous Jow grade mutual stimu-
lation bodywide by the coexisting donor and recipient cell 
populations,2 the process involving the release of differing 
groups of cytokines (TH 1 vs TH2). 
The observations in the total 23 cases herein reported 
are reminiscent of those reported in dogs nearly 25 years 
ago after orthotopic canine transplantation. The animals 
that survived for 4 months under azathioprine therapy 
could almost always be maintained for long nonrejecting 
periods thereafter (eventually out to 12 years) without 
further treatment.8 This was in contrast to canine renal 
recipients that rejected their kidneys early and far more 
frequently. As the result of seeing the same thing in 
patients, we suspect that the majority of human liver 
recipients who have had a benign postoperative course do 
not need immunosuppression if they are significantly be-
yond 5 years. 
Because immunosuppression has liability, particularly 
in children who have a high cumulative incidence of 
PTLD, we have begun a prospective trial of drug weaning 
in 50 long-surviving liver recipients. The safety of such a 
trial has been illustrated by the ease with which signs of 
presumed rejection could be controlled as in the one 
patient suspected to have this diagnosis in the currently 
reported series. In this patient whose immunosuppression 
was restarted with a prompt response, the original disease 
that destroyed her native liver was PBC. An occult danger 
of stopping immunosuppression in patients with autoim-
mune hepatic disorders could be the development of these 
diseases (PBC, autoimmune hepatitis, and others) in the 
allograft, a possibili.y that will have to be carefully looked 
for in future cases. 
It is possible that an apparent flare up of rejection after 
drug discontinuance can be managed in some patients (as 
in Patient 15) without resuming immunosuppression. A 
"rebound cellular response" and spontaneous subsequent 
remission have been reported in experimental animals 
when immunosuppression was stopped.9 The decision to 
continue withholding therapy for Patient 15 was crucial 
because of her recurrent PTLD, and was rewarded by 
normalization of her liver function with no further lym-
phoma recurrence. 
The duration of follow-up before drugs can be stopped 
with a high expectation of success is not known, nor is it 
predictable with any currently available method of screen-
ing. In one extraordinary case, a noncompliant 15-year-old 
girl who did not appear to be overimmunosuppressed 
stopped all treatment at 6 months, and has a perfect result 
14.3 years later. Those experienced in liver recipient 
management would recoil at considering such a dangerous 
step, and no patient in our prospective program would be 
a candidate for weaning before at least 5 years of uninter-
rupted therapy. 
However, discontinuance much earlier than this was 
mandated in the 10 patients who had life-threatening 
complicati,ons, of which the most common was PTLD. The 
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ability to stop treatment so early cannot be construed as a 
guideline in patients without such evidence of overimmu· 
nosuppression, particularly if all other prognostic factors 
are favorable. Apart from iatrogenic immunosuppression, 
an augmenting immunosuppressive factor could be the 
PTLD itself. Studies on adult liver recipients with PTLD 
using snap frozen liver biopsy tissues were analyzed by 
peR and found to be positive for EBV,.IL-4, and IL-IO 
mRNA and negative for IL-2 and IFN-gamma (Dr Michael 
Nalesnik, unpublished observations). Thus, the tolero-
genic cytokine pattern with TH2 dominance could be 
facilitated by PTLD and other viral infections. 
Although there is evidence that the same mechanisms 
apply generically to all whole organ allografts, the migra-
tory cell constituency of other kinds of grafts is smaller 
than the liver, explaining on one hand the high tolerogenic 
potential of the liver, and emphasizing on the other the 
much greater risk of drug weaning should this be unwisely 
attempted in recipients of leukocyte-poor organs such as 
the kidney and heart. The strategy of augmenting the 
natural migratory traffic in these organs with bone marrow 
has been discussed elsewhere. I ,5 
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